Pharmacokinetics of Propranolol

Overview

Journal J Pharmacokinet Biopharm

Specialty Pharmacology

Date 1981 Aug 1

PMID 7310641

Citations 10

Authors

L Borgstrom

C G Johansson

H Larsson

R Lenander

Affiliations

Soon will be listed here.

Abstract

The pharmacokinetics of propranolol after the administration of 40, 80, and 120 mg p.o. and 10 mg i.v. was studied in nine healthy male volunteers. Propranolol was analyzed after extraction and derivatization by gas-liquid chromatography. A multiexponential curve-stripping program was used for the pharmacokinetic analysis. The volume of distribution was about 6 liters . kg-1, bioavailability around 25%, with a mean terminal half-life of 6 hr. There was no evidence of either dose dependent disposition kinetics or an oral threshold dose. A slight increase in urine volume was observed after propranolol administration.

Citing Articles

DigiLoCS: A leap forward in predictive organ-on-chip simulations.

Aravindakshan M, Mandal C, Pothen A, Schaller S, Maass C PLoS One. 2025; 20(1):e0314083.

PMID: 39787162 PMC: 11717216. DOI: 10.1371/journal.pone.0314083.

Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs.

Pardridge W Pharm Res. 2023; 40(3):661-674.

PMID: 36829100 PMC: 10036418. DOI: 10.1007/s11095-023-03484-2.

Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma.

Takechi T, Kumokawa T, Kato R, Higuchi T, Kaneko T, Ieiri I J Clin Pharmacol. 2018; 58(10):1361-1370.

PMID: 29746707 PMC: 6175224. DOI: 10.1002/jcph.1149.

Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations.

Del Frari L, Leaute-Labreze C, Guibaud L, Barbarot S, Lacour J, Chaumont C Pharmacol Res Perspect. 2018; 6(3):e00399.

PMID: 29736244 PMC: 5925426. DOI: 10.1002/prp2.399.

Propranolol reduces reference-dependence in intertemporal choice.

Lempert K, Lackovic S, Tobe R, Glimcher P, Phelps E Soc Cogn Affect Neurosci. 2017; 12(9):1394-1401.

PMID: 28992268 PMC: 5737445. DOI: 10.1093/scan/nsx081.

References

Hayes A, Cooper R . Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey. J Pharmacol Exp Ther. 1971; 176(2):302-11. View

Cotham R, Shand D . Spuriously low plasma propranolol concentrations resulting from blood collection methods. Clin Pharmacol Ther. 1975; 18(5 Pt 1):535-8. DOI: 10.1002/cpt1975185part1535. View

SHAND D, Nuckolls E, OATES J . Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther. 1970; 11(1):112-20. DOI: 10.1002/cpt1970111112. View

Evans G, SHAND D . Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther. 1973; 14(4):487-93. DOI: 10.1002/cpt1973144part1487. View

IMBS J, SPACH M, Scmidt M, Schwartz J . [Effect of propranolol on urine concentration]. Therapie. 1977; 32(3):329-35. View

Weiss Y, Safar M, Chevillard C, Frydman A, Simon A, Lemaire P . Comparison of the pharmacokinetics of intravenous dl-propranolol in borderline and permanent hypertension. Eur J Clin Pharmacol. 1976; 10(6):387-93. DOI: 10.1007/BF00563074. View

George C, Fenyvesi T, Conolly M, Dollery C . Pharmacokinetics of dextro-, laevo- and racemic propranolol in man. Eur J Clin Pharmacol. 1972; 4(2):74-6. DOI: 10.1007/BF00562500. View

Davies R, Pickering T, Morganti A, Bianchetti G, Morselli P, Romankiewicz J . Beta-blockade and blood-levels after low-dose oral propranolol: The hepatic "first-pass" threshold revisited. Lancet. 1978; 1(8061):407-10. DOI: 10.1016/s0140-6736(78)91201-1. View

Di Salle E, Baker K, Bareggi S, Watkins W, Chidsey C, Frigerio A . A sensitive gas chromatographic method for the determination of propranolol in human plasma. J Chromatogr. 1973; 84(2):347-53. DOI: 10.1016/s0021-9673(01)91714-5. View

10.

Gomeni R, Bianchetti G, Sega R, Morselli P . Pharmacokinetics of propranolol in normal healthy volunteers. J Pharmacokinet Biopharm. 1977; 5(3):183-92. DOI: 10.1007/BF01065394. View

11.

SHAND D, Rangno R . The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology. 1972; 7(3):159-68. DOI: 10.1159/000136285. View

12.

Evans G, Nies A, SHAND D . The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther. 1973; 186(1):114-22. View

13.

Borgstrom L, Johansson C, Larsson H, Lenander R . Pharmacokinetics of bendroflumethiazide after low oral doses. J Pharmacokinet Biopharm. 1981; 9(4):431-41. DOI: 10.1007/BF01060887. View

14.

Walle T . GLC determination of propranolol, other beta-blocking drugs, and metabolites in biological fluids and tissues. J Pharm Sci. 1974; 63(12):1885-91. DOI: 10.1002/jps.2600631212. View

15.

Evans G, SHAND D . Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man. Clin Pharmacol Ther. 1973; 14(4):494-500. DOI: 10.1002/cpt1973144part1494. View

16.

Chidsey C, MORSELLI P, Bianchetti G, Morganti A, Leonetti G, Zanchetti A . Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation. 1975; 52(2):313-8. DOI: 10.1161/01.cir.52.2.313. View

17.

TARAZI R, Frohlich E, DUSTAN H . Plasma volume changes with long-term beta-adrenergic blockade. Am Heart J. 1971; 82(6):770-6. DOI: 10.1016/0002-8703(71)90198-0. View

18.

Nies A, SHAND D . Clinical pharmacology of propranolol. Circulation. 1975; 52(1):6-15. DOI: 10.1161/01.cir.52.1.6. View